Mirza, Kazim and Landoski, Kathryn and Thakar, Dilip and Heir-Singh, Jagtar and Jackson, Timothy and Kassab, Cynthia (2020) Sugammadex-Associated Hypotension, Bradycardia, Asystole, and Death. Case Reports in Anesthesiology, 2020. pp. 1-2. ISSN 2090-6382
8767195.pdf - Published Version
Download (1MB)
Abstract
On December 16, 2015, the Food and Drug Administration (FDA) in the United States approved sugammadex (Bridion, Merck and Co), a modified gamma-cyclodextrin, to be used as a reversal agent. It is a first and unique selective nondepolarizing steroidal muscle relaxant (NDSMR) binding agent with a great affinity for rocuronium and vecuronium. However, there have been several recently published case reports of bradycardia and asystole immediately after sugammadex administration for the reversal. This report presents a case of sugammadex administration followed by rapidly progressing bradycardia leading to asystole and subsequent death. The family has provided the written consent to share this case report.
Item Type: | Article |
---|---|
Subjects: | Journal Eprints > Medical Science |
Depositing User: | Managing Editor |
Date Deposited: | 25 Nov 2022 04:59 |
Last Modified: | 25 May 2024 07:44 |
URI: | http://repository.journal4submission.com/id/eprint/342 |